Beginngs Consortium News Today

The consortium involved in the newborn genomic sequencing initiative consists of a diverse and growing selection of stakeholders.

Catherine Nester, RN, vice president of physician and patient strategies at Inozyme Pharma, highlights the importance of newborn screening for rare diseases and the impact of the BeginNGS diagnostic tool.

The BeginNGS program added 23 new founding members to the consortium and expanded to include 31 additional genetic disorders in its second phase screening, totaling 419 treatable genetic disorders.

15.08.2022 - - Recently reported positive preliminary biomarker and safety data from ongoing Phase 1/2 clinical trials of INZ-701 in ENPP1 Deficiency and ABCC6 Deficiency – - Appointed Kurt Gunter, M.D. as senior vice president and chief medical officer - - ...